Dr. Reddy’s Bachupally plant experiences a version of FDA deja vu

Dr. Reddy's logo on capsules
Dr. Reddy's has had its formulation plant in Bachupally, Hyderabad, again cited by the FDA. (Dr. Reddy's)

A Dr. Reddy’s formulation plant in India appears stuck on regulatory repeat. The drugmaker reported that the FDA had completed an inspection of the facility in Bachupally and cited it with 11 violations. When the FDA inspected the plant in 2017 it was cited with—you've got it—11 violations.

In a filing (pdf) Friday with the Bombay Stock Exchange, Dr. Reddy’s did not hint at the nature of the observations, simply saying that it will address the violations at its Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad, "comprehensively within the stipulated timeline.”

In 2017, the Indian company claimed that the observations were mostly procedural, “reflecting the need to improve people capabilities and strengthen documentation and laboratory systems.” Later that year, it reported the FDA had cleared the plant in an establishment inspection report.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The company’s extensive manufacturing network has stacked up quite a few FDA citations in recent years. Last September, the agency issued eight observations to Dr. Reddy’s oncology formulation facility in Duvvada, India. It is one of three facilities cited in a scathing warning letter in 2015 that raised issues about the potential for contamination. A follow-up inspection of that facility two years later found more than a dozen issues, some of them repeats.

RELATED: Dr. Reddy’s says FDA finds more issues at oncology drug plant

While the regulatory problems have created some drag on the company’s finances, it recently reported (PDF) that revenues for the quarter ended Dec. 31, 2018, were up slightly at $553 million. Sales in North America, where the entire generics market has been soft for several years, were down 8% to $208 million. North American sales account for nearly 40% of Dr. Reddy’s revenues. Sales in emerging markets, which account for about 20% of its revenues, were up 31% to $108 million.


Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.